Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Quest Diagnostics reported Q3 2026 revenue of $3.10 billion, up 10.0% year-over-year, with reported diluted EPS of $2.78 (up 28.7%) and adjusted EPS of $3.00 (up 15.4%). The company raised full-year 2026 guidance: revenues to $12.065-$12.105 billion, adjusted EPS to $11.25-$11.35, and operating cash flow to approximately $1.90 billion. Growth was driven by 14.4% organic requisition volume gains across physician, hospital and consumer channels, though revenue per requisition fell 4.2%.
Key figures
- Eps
- 2.78
- Revenue
- 3097000000
- Guidance
- FY26 net revenues $12.065B-$12.105B (raised from $11.95B-$12.05B); reported diluted EPS $10.21-$10.31 (from $9.97-$10.17); adjusted diluted EPS $11.25-$11.35 (from $11.05-$11.25); operating cash flow ~$1.90B (from ~$1.80B)
- Revenue Yoy
- 10.0%
- Adjusted eps
- 3
- Adjusted eps yoy
- 15.4%
- Operating income
- 479000000
- Reported eps yoy
- 28.7%
- Nine month revenue
- 9035000000
- Operating income yoy
- 24.2%
- Q3 operating cash flow
- 611000000
- Revenue per requisition yoy
- -4.2%
- Organic requisition volume growth
- 14.4%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.